Genentech Reorganizing Facility Following FDA Inspection And Warning Letter
Executive Summary
Genentech is reorganizing its manufacturing operations in an attempt to address multiple FDA concerns regarding its South San Francisco, Calif., manufacturing facility following an August inspection, the company said.
You may also be interested in...
Genentech Pulmozyme
Firm recalls one lot (500 cartons) of dornase alfa cystic fibrosis therapy after finding small punctures in some of the ampules upon shipping. Company recalled 23 lots of the drug a year ago due to similar ampule leakage problems, citing packaging defects. Genentech recalled a Pulmozyme lot in February in conjunction with the reorganization of its South San Francisco manufacturing facility following a warning letter (1"The Pink Sheet" Jan. 1, p. 28)
Genentech Pulmozyme
Firm recalls one lot (500 cartons) of dornase alfa cystic fibrosis therapy after finding small punctures in some of the ampules upon shipping. Company recalled 23 lots of the drug a year ago due to similar ampule leakage problems, citing packaging defects. Genentech recalled a Pulmozyme lot in February in conjunction with the reorganization of its South San Francisco manufacturing facility following a warning letter (1"The Pink Sheet" Jan. 1, p. 28)
Genentech Xolair Brand Awareness Reaches 55% Among Allergists
Brand awareness of Genentech's asthma drug Xolair (omalizumab) is over 50% among allergists as a result of Genentech's market preparation efforts, compared to 48% in the first quarter, Chief Operating Officer Myrtle Potter reported during an analyst meeting in New York City Feb. 21.